BA supplementation improves recovery after 5-FU chemotherapy. (A) The experimental setup of TUDCA supplementation in 5-FU–treated mice. (B-D) Cellularity in BM of TUDCA-treated mice on day 6. Total BM cells (B), lineage⁻ cells (C), and HSPCs (defined as lineage⁻CD48⁻CD244⁻CD150⁺ cells) (D) in femur and tibia are shown (n = 10-11). (E-H) Cellularity in BM of TUDCA-treated mice on day 8. Total BM cells (E), myeloid cells (F), lymphoid cells (G), and lineage⁻ cells (H) in femur and tibia are shown (n = 14-15). (I) Flow cytometry plots showing the Sca-I and c-kit expression pattern on lineage⁻ BM cells of PBS- and TUDCA-treated mice on day 8. The gate represents c-kit⁺Sca-I⁺lineage⁻ (KSL) cells. (J-L) Cellularity of primitive cells in BM of the TUDCA-treated mice on day 8. c-Kit⁺ cells (J), KSL cells (K), and HSCs (defined as CD150⁺CD48⁻KSL) (L) in femur and tibia are shown (n = 14-15). Results are presented as means ± SEM. *P < .05; **P < .01; ***P < .001; ****P < .0001.